Cancer incidence in the first-degree relatives of ovarian cancer patients. by Auranen, A. et al.
British Journal of Cancer (1996) 74, 280-284
i (B) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Cancer incidence in the first-degree relatives of ovarian cancer patients
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Summary Cancer incidence was studied among 3072 first-degree relatives of 559 unselected ovarian cancer
patients. Among cohort members there were 306 cancer cases. The overall cancer incidence was not increased:
the standardised incidence ratio (SIR) in males was 0.9 (95% confidence interval 0.8-1.1) and in females 1.0
(0.8-1.1). The female relatives had a significantly increased risk for ovarian cancer (SIR 2.8, 1.8-4.2). The
excess was attributable to sisters only (SIR 3.7, 2.3-5.7). The relative risk for ovarian cancer among sisters
decreased both by increasing age of the sister and by increasing age at diagnosis of the index patient: the SIRs
were 7.3 (1.5-21.4), 4.5 (1.6-9.8) and 3.1 (1.7-5.4) for sisters of index patients diagnosed in age <45, 45-54
and 55-75 years respectively. The age dependency of the risk supports the role of genetic factors in familial
ovarian cancer. Although the risk of ovarian cancer among sisters from families with breast cancer (SIR 9.2,
3.7-19.0) was significantly higher than among sisters from families with no breast cancer patients (SIR 2.9,
1.6-4.8, rate ratio 3.1, P < 0.05), the excess was not solely attributable to coaggregation of breast and ovarian
cancer. Among the 27 families with two or more ovarian cancers, only sisters were affected in 24 families,
which might implicate recessive inheritance or shared environmental factors influencing ovarian cancer risk in
sisters.
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One of the strongest known risk factors for epithelial ovarian
cancer is family history of the disease (Hartge et al., 1989). In
case-control studies including sufficient numbers of patients,
the age-adjusted relative risk estimates for the first-degree
female relatives of ovarian cancer patients have ranged from
1.9 to 4.5 (Parazzini et al., 1992; Houlston et al., 1993;
Hartge et al., 1989; Schildkraut et al., 1989; Kerber and
Slattery, 1995). In a combined analysis of seven case-control
studies with altogether 1122 patients with an invasive
epithelial ovarian carcinoma and 5359 controls, the age-
adjusted relative risk was estimated to be 5.4 (Hartge et al.,
1994). Familial aggregation of ovarian cancer, originally
detected in individual families (Liber, 1950; Lewis and Clare
Davison, 1969; Li et al., 1970; Fraumeni et al., 1975; Thor et
al., 1976), is thus convincingly demonstrated also in
epidemiological studies.
Causes for this familial aggregation are largely unknown.
An undetermined fraction of familial ovarian cancer is
probably caused by inherited mutations in the recently
cloned gene BRCAI (Miki et al., 1994; Shattuck-Eidens et
al., 1995). Mutations in the BRCAJ gene are estimated to be
involved in 92% of breast-ovarian cancer families (Narod et
al., 1995), but site-specific ovarian cancer has also been
reported to be linked to this gene (Steichen-Gersdorf et al.,
1994). Inherited mutations in the genes involved in the
hereditary non-polyposis colorectal cancer, HNPCC, also
predispose to ovarian cancer (Lynch et al., 1986; Mecklin and
Jarvinen 1991; Aaltonen et al., 1994). However, the most
common form of familiality of ovarian cancer is the
occurrence of only two ovarian cancer cases in the family,
without features of these dominantly inherited cancer
syndromes (Piver et al., 1993; Greggi et al., 1990; Grover et
al., 1993).
The present study aims to give a more precise picture of
the familial risk of ovarian cancer than has been possible in
previous studies. The Finns are a genetically homogeneous
and stable population. Population registration in Finland is
comprehensive and reliable. The nationwide Finnish Cancer
Registry has been operating since 1953 registering over 99%
of all solid tumors in Finland (Teppo et al., 1994). It was
possible therefore, for us to use high quality data from
genealogical registers and medical records. With this
population-based design we were able to avoid major biases
in relation to patient selection, follow-up and risk estimation.
Materials and methods
Description of the data sources
The population-based and nationwide Finnish Cancer
Registry was founded in 1952 and cancer registration started
in 1953. Reporting of cancer cases to the registry was made
obligatory in 1961. Physicians, hospitals and pathology
laboratories send reports to the registry independently. On
average, five notifications are received per case. In the years
1953-1966, the registration was done manually using
alphabetical patient name files. From the beginning of 1967
the register was computerised on the basis of the unique
personal identification numbers given to residents of Finland.
The Registry's files are annually linked to the file of deaths
and emigrations issued by the Finland Statistics and
Population Register Centre. Complete follow-up of cancer
patients is achieved.
Population registration in Finland has traditions dating
back to the 16th century and is considered to be of excellent
quality. Local population registries are kept by the church
parishes and, for people not belonging to any religious
community, by local authorities. From 1964 this information
is also registered in a nationwide population registry, kept by
the Population Register Centre.
Index patients and relatives
From the Finnish Cancer Registry, all women who had an
invasive epithelial ovarian cancer diagnosed during the years
1980-1982 under 76 years of age, were selected as index
patients; they numbered 863.
The local registries of the communities where the patients
were born were contacted to obtain the names and birth
dates of the parents and siblings. In cases in which the family
had moved to another community, tracing was continued
until either of the parents deceased or the mother reached 50
years of age and further pregnancies were considered
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unlikely. The parents and siblings were followed up through
the parish records until death or until they obtained a
personal identification number. The data on the children and
husbands were obtained from the parishes or the Central
Population Register. The data on relatives were linked with
the Central Population Register in February 1994 to obtain
dates of death of the relatives.
Tracing of family members was successful for 700 (81%)
of the 863 index patients. Failure to trace the family members
was due to: inability to find the patient in the population
registries of her reported birthplace, probably owing to
inaccurately provided birthplace (90 patients), lack of
response from the local officials (25 patients), born abroad
(five patients) or failure to follow the family until additional
children were considered unlikely, caused by the fact that the
family had changed location repeatedly (43 patients).
Among the above 700 families, follow-up for 273 persons
altogether in 141 families had to be interrupted for practical
causes before death or assignment of a personal identification
number. In the remaining 559 families all the family members
were followed up. The final analysis was restricted to these
559 families. The distribution of the 559 index patients
according to age and histology is presented in Table I.
Statistical methods
The relatives were followed up for cancer through the files of
the Finnish Cancer Registry. For relatives who died in the
period 1953 to 1966 the follow-up was done manually using
the alphabetical patient name files with date of birth and
place of birth and residence as an additional key. For those
alive after 1 January 1967 the follow-up was done
automatically using the personal identification number as
the key. For mothers and sisters deceased during the period
1936-52, death certificates were obtained to verify the cause
of death. For people deceased before 1936, death certificates
are not available.
To validate the data and to determine the starting point of
the analysis, the overall cancer risk was first calculated
separately for the period 1953-1966. The standardised
incidence ratios (SIRs) for overall cancer in females and
males were 0.7 (95% CI 0.5- 1.0) and 0.7 (95% CI 0.5- 1.0)
respectively. This significant risk deficit was considered to
reflect problems encountered in the manual follow-up of the
relatives. In consequence, the data were not considered
reliable for the period 1953-1966, and the main analysis
was restricted to the period starting from 1 January 1967.
Follow-up for cancer among parents of the index patients
started at date of birth of the index patient or on 1 January
1967, whichever was later, and ended at death or on 31
December 1993, whichever was first. For siblings and
children the follow-up started at the date of their birth or
Table I Distribution of 559 index patients diagnosed with invasive
epithelial ovarian cancer under 76 years of age in Finland in 1980-












Clear cell 24 (4%)
Anaplastic 37 (7%)
Unspecified adenocarcinoma 213 (38%)
Total 559 (100%)
on 1 January 1967, whichever was later. Siblings' person-
years at risk during the follow-up were categorised into four
age groups.
The numbers of observed cases and person-years at risk
in each relative category were counted, by five year age
groups, separately for three calendar periods (1967-75,
1976-84 and 1985-93). The expected numbers of cases for
total cancer and for specific cancer types were calculated by
multiplying the number of person-years in each age group
by the corresponding period-specific cancer incidence in all of
Finland.
The specific cancer types selected a priori for the analysis
included the cancer sites with known or suspected exceptional
risk in earlier studies, and other common cancer types to give
the whole picture of the cancer situation among the cohort.
The selected cancers were: ovary, breast, cervix uteri,
endometrium, prostate, stomach, colon, rectum, lung,
pancreas and melanoma of the skin.
Because of the definition of the index patients, the
expected number for ovarian cancer during the period
1980-82 in ages below 75 was subtracted from the total
expected number of cases for female overall cancer and
ovarian cancer. The decision to exclude observed and
expected numbers for the whole period 1980-82 is
unbiased. There were no families with more than one
ovarian cancer diagnosed in 1980-82.
Standardised incidence ratios (SIRs) were defined as ratios
of the observed to the expected number of cases. The
statistical significance was tested by the Mantel-Haenszel
chi-square test and 95% confidence intervals (CIs) were
calculated on the presumption that the number of observed
cases followed a Poisson distribution.
Results
In the 559 families there were 6501 first-degree relatives.
Ovarian cancer was diagnosed in 31 relatives from 27
families. Eight of the cancers were diagnosed before the
start of the follow-up period in 1967. Two ovarian cancers
were present in 23 families (4.1% of all families) and three
ovarian cancers in four families (0.7% of all families). Three
mothers and 28 sisters were affected. In the four families with
three ovarian cancer patients, only sisters were affected in two
families and two sisters and a mother in one family. In the
fourth family, only sisters were affected with ovarian cancer,
but the mother had an abdominal cancer of undefined origin.
Breast cancer was present in ten of these 27 families.
Of the relatives, 3072 were at risk on 1 January 1967 or
thereafter. They were followed up for a total of 69 793
person-years (mean 23 years). The overall risk ofcancer was
not increased among the relatives (Table II). Female relatives
had a significantly increased 2.8-fold risk (95% CI 1.8-4.2)
for ovarian cancer, but no other significantly increased or
decreased risks were observed (Table III). The mothers' SIR
for ovarian cancer was 0.6 (0.0-3.1) while the sisters' SIR
Table II Numbers (n) of relatives and observed numbers (Obs) and
standardised incidence ratios (SIR) with 95% confidence intervals
(CI) of all cancers in the first-degree relatives in 1967-93 of 559
index patients diagnosed with an invasive epithelial ovarian cancer
in Finland 1980-82
Relative n Obs SIR CI
Female 1605 156 1.0 0.8-1.1
Mothers 287 35 0.8 0.5-1.1
Sisters 918 116 1.0 0.9- 1.2
Daughters 400 5 0.6 0.2- 1.4
Male 1467 151 0.9 0.8-1.1
Fathers 171 39 1.1 0.8- 1.4
Brothers 861 107 0.9 0.7- 1.1
Sons 435 5 0.9 0.3-2.0Cancer in reladves of ovarian cancer patients
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was 3.7 (2.3 -5.7). The relative risk for ovarian cancer among
sisters decreased by increasing age of the sister and by
increasing age of the index patient (Table IV). Apart from
ovarian cancer, no significantly increased or decreased risks
were observed when the mothers and sisters were analysed
separately. The SIR for breast cancer in mothers was 0.9
(0.4-1.8) and in sisters 1.0 (0.6-1.4).
In sisters, stratification of the data according to the age at
diagnosis of the index patients into three groups (<45 years,
45-54 years and 55-75 years) revealed that the sisters of the
youngest index patients had a significantly increased overall
cancer risk (SIR 2.1, 1.1-3.6) and the risk was concentrated
in sisters aged 45 to 59 years (SIR 2.9, CI 1.4-6.0). This
excess was attributable to ovarian cancer only.
No significantly increased or decreased risks were observed
in the male relatives (Table III). Division of the males into
fathers and brothers did not change the results. For brothers,
the data were further stratified according to the age of the
index patient into three age groups, as described above. No
increase in overall cancer risk or risk for any specific cancer
was observed in any age category.
Of the 918 sisters at risk, 118 (13%) sisters belonged to
families with breast cancer (either in index patient or
relative). The risk of ovarian cancer was significantly higher
among sisters from families with breast cancer (SIR 9.2, 3.7-
19, n=7) compared with sisters from families with no breast
cancer patients (SIR 2.9, 1.6-4.8, n= 15, rate ratio 3.1, P <
0.05). In the 27 families with two or more ovarian cancers,
1.6 breast cancers were expected in the sisters but seven were
Table III Observed (Obs) and expected (Exp) numbers and
standardised incidence ratios (SIR) with 95% confidence intervals
(CI) of specific cancers in the first-degree relatives in 1967-93 of
559 index patients diagnosed with an invasive ovarian cancer in
Finland in 1980 -82
Site Obs Exp SIR 95% CI
Breast 37 38.8 0.9 0.7-1.3
Ovary 23 8.2 2.8 1.8-4.2
Cervix uteri 6 5.0 1.2 0.4-2.6
Endometrium 14 10.1 1.4 0.8-2.3
Prostate 18 23.3 0.8 0.5-1.2
Stomach
Female 11 12.9 0.8 0.4-1.5
Male 20 15.4 1.3 0.8-2.0
Colon
Female 6 10.3 0.6 0.2-1.3
Male 6 6.8 0.9 0.3-1.9
Rectum
Female 6 6.7 0.9 0.3-2.0
Male 6 6.3 1.0 0.4-2.1
Pancreas
Female 4 6.9 0.6 0.2- 1.5
Male 6 6.3 1.0 0.4-2.1
Lung
Female 7 6.6 1.1 0.4-2.2
Male 40 44.0 0.9 0.6- 1.2
Melanoma
Female 1 3.6 0.3 0.0-1.6
Male 4 3.2 1.3 0.4-3.2
observed (SIR 4.3, 1.7 -8.8). The risk was significantly
increased only in sisters between 60 and 74 years of age
(SIR 6.7, CI 1.8-17.1). The occurrence of breast cancer or
more than one ovarian cancer in the family did not affect the
brothers' risk for cancer in any of the analysed sites, and the
occurrence of gastric or colorectal cancer in the families did
not increase the brothers' or the sisters' risk for any cancers.
Discussion
In the present study of Finnish patients we were able to
demonstrate familial aggregation of ovarian cancer in 27 of
559 studied families. The relative risk for ovarian cancer
among first-degree relatives was 2.8 being basically of similar
magnitude to that reported in previous studies (Parazzini et
al., 1992; Houlston et al., 1993; Hartge et al., 1989;
Schildkraut et al., 1989; Kerber and Slattery 1995). The
cumulative incidence of ovarian cancer in Finland to the age
of 75 is 1.4%. Presuming a minimum life-time relative risk of
3.5 in sisters, this corresponds to a minimum 5% likelihood
of getting ovarian cancer by this age.
The significance of the age at onset of ovarian cancer to
the familiality of the disease has been a controversial issue.
Some studies have detected no relationship between
familiality and age at onset of ovarian cancer (Parazzini et
al., 1992; Narod et al., 1994; Kerber and Slattery 1995), while
other studies suggest that familial occurrence of ovarian
cancer is increased at younger (Lynch et al., 1993; Houlston
et al., 1993) or older (Schildkraut et al., 1989) ages at onset.
The relation of young age to the familiality of the disease,
observed in this study, is typical for inherited predisposition
and resembles the pattern previously observed (Houlston et
al., 1993). Their data were collected from healthy relatives
consulting an ovarian cancer screening clinic. Since relatives
of younger cancer patients could be presumed to be more
worried about the familiality of cancer than relatives of older
patients, a possible bias towards younger index patients
might have occurred in their study. Such a bias does not exist
in our population-based study.
The observation that only sisters had an increased risk for
ovarian cancer, whereas no increase in risk could be observed
for mothers, would speak for a recessive rather than a
dominant mode of transmission. However, close to 50% of
mothers were deceased before the follow-up period. During
the follow-up period starting from 1967, the number of
person-years at risk for mothers at younger ages is limited
and the age patterns of person-years at risk are different for
mothers and sisters. The overall difference between the SIRs
of the sisters and mothers (higher SIR among sisters than
mothers) is not statistically significant, and because of the
decreasing relative risk by increasing age, adjustment for age
would further diminish this difference.
When the causes of death for relatives who died before
1967 were verified from death certificates or from the Finnish
Cancer Registry, only two further ovarian cancers were found
among the mothers. The notable lack ofovarian cancer in the
mothers may implicate recessive inheritance or shared
environmental risk factors in sisters. Although the findings
Table IV Observed (Obs) numbers and standardised incidence ratios (SIR) with 95% confidence intervals (CI) of ovarian cancer
by age of the index patient and by age of the sister in the sisters of the 559 index patients diagnosed with invasive epithelial
ovarian cancer in Finland 1980-82
Age of the index patient at diagnosis
Age ofthe sister <45 years 45-54 years 55-75 years Whole cohort
duringfollow-up Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI
30-44 2 15.4 1.9-55.6 1 5.6 0.1-30.9 1 8.3 0.2-46.4 4 9.3 2.5-23.8
45-59 1 5.6 0.1 -31.0 4 5.9 1.6-15.1 3 2.5 0.5-7.2 8 3.9 1.7-7.6
60-74 - 0.0 0.0-63.2 1 2.3 0.0- 13.0 9 4.3 2.0-8.1 10 3.8 1.8-7.1
75+ - 0.0 0.0-4100 - 0.0 0.0-189 - 0.0 0.0-5.2 - 0.0 0.0-5.0
All ages 3 7.3 1.5-21.4 6 4.5 1.6-9.8 13 3.1 1.7-5.4 22 3.7 2.3-5.7Cancer in relativs of ovarian cancer patents
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in most studies speak for a dominantly inherited predisposi-
tion (Houlston et al.. 1991: Lynch et al.. 1991). the possibility
of a recessive inheritance, based on the observation of
consanguinity among patients with ovarian cancer. has also
been raised (Cramer et al.. 1983). In the OPCS study from
England and Wales (Easton et al.. 1996), sisters of ovarian
cancer cases had higher mortality from this disease than
mothers. which supports the observations in the present
study.
We did not detect an increase in breast cancer risk among
all the relatives of the ovarian cancer patients. Ovarian cancer
is known to be genetically related to breast cancer in the
breast-ovarian cancer syndrome (Lynch et al.. 1974; Go et
al.. 1983). which is mainly caused by inherited mutations in
the recently cloned BRCA1 gene (Miki et al., 1994; Narod et
al.. 1995). Some of the previous studies have detected a small
but significant increase in breast cancer risk among relatives
of ovarian cancer patients. which has been interpreted as
reflecting the existence of the breast-ovarian cancer
syndrome in the study populations (Houlston et al.. 1993:
Schildkraut et al.. 1989). If so. our finding might imply that
BRCAI gene mutations causing both breast and ovarian
cancer are so infrequent among Finnish ovarian cancer
patients that their effect is not visible at the population level.
The association of breast and ovarian cancer was also
evident in the present study. In all. 30% of ovarian cancers in
sisters were observed among the 13% of sisters belonging to
families with breast cancer. However, 70% of familial
ovarian cancer could not be explained by coaggregation of
breast and ovarian cancer. which suggests that in the
majority of the families with two or more ovarian cancers.
inherited mutations predisposing to both breast and ovarian
cancer are not involved. In the OPCS study (Easton et al.,
1996). it was calculated on the basis of BRCAJ gene
frequency estimates that BRCAJ would account for 57% of
the excess familial risk of ovarian cancer below age 70.
In contrast to previous studies (Cramer et al.. 1983:
Schildkraut et al.. 1989: Slatterv and Kerber 1994) we did not
detect any increased risk of colon or gastric cancer in the
relatives of ovarian cancer patients. Ovarian cancer and colon
cancer are known to be genetically related in the hereditary
non-polyposis colorectal cancer (HNPCC) syndrome (Lynch
et al.. 1986: Aaltonen et al.. 1994). but ovarian cancer is rare
in this syndrome. representing only 4% of the cancers in the
HNPCC families (Mecklin and Jarvinen 1991). Typical
HNPCC families are rare in Finland: less than a hundred
typical HNPCC families have been identified to date (L
Aaltonen. personal communication). We presume that no
HNPCC families were among the studied families.
Only index patients having an invasive cancer with
histology coded as epithelial were selected for this study.
Close to 40% of these cancers were reported to the Cancer
Registry only as adenocarcinoma without further specifica-
tion. Therefore. analysis of separate histologies was not
considered useful. The significance of histology can be better
evaluated by investigating the familial ovarian tumours in
more detail.
The strength of this study was the reliable detection of the
relatives' cancers through the nationwide Finnish Cancer
Registry. It was also possible for us to compare the cancer
risk among the relatives with that in the underlying
population drawn from the same database as the observed
cases; potential biases involving differences between numera-
tor and denominator were thereby avoided. Using incidence
instead of mortality avoids errors in the stated underlying
cause of death and also the biases caused by differences in
survival of cases in the cohort and referent population.
This dataset represents all the familial cases of ovarian
cancer that could be detected among Finnish ovarian cancer
patients diagnosed during a 3 year period. regardless of the
cause of the familiality. The sisters of ovarian cancer patients
were found to have a significantly increased risk for ovarian
cancer. and the risk increase was age related. being highest in
the sisters of the youngest ovarian cancer patients. Nothing
conclusive can be stated about the mode of inheritance. but
the possibility of recessive inheritance was not excluded. Less
than half of this observed familiality could be explained by
coaggregation of breast and ovarian cancer in the family. A
detailed genetic analysis of the tumours from these patients
with familial ovarian cancer should further clarify whether
the observed familiality is partly or completely caused by
already known gene mutations or whether other as yet
unknown mechanisms or gene defects are also involved.
Acknowledgements
This study was supported by the Finnish Cancer Foundation. the
Turku University Foundation and the Ida Montin Foundation.
References
AALTONEN LA. PELTOMAKI P. MECKLIN J-P. JARVINEN H. JASS
JR. GREEN JS. LYNCH HT. WATSON P. TALLQVIST G. JUHOLA
M. SISTONTEN' P. HAMILTON SR. KIN-ZLER KW. VOGELSTEIN B
AND DE LA CHAPELLE A. (1994). Replication errors in benign
and malignant tumors from hereditary nonpolyposis colorectal
cancer patients. Cancer Res.. 54, 1645- 1648.
CRAMER DW. HUTCHISON GB. WELCH WR. SCULLY RE AND
RYAN KJ. (1983) Determinants of ovarian cancer risk. I.
Reproductive experiences and familyv histor-. J. Natl Cancer
Inst.. 71, 711-716.
EASTON DF. MATTHEWS FE. FORD D. SWERDLOW AJ AND PETO J.
(1996). Cancer mortality in relatives of women with ovarian
cancer: the OPCS stud. Int. J. Cancer. 65, 284-294.
FRAUMENI JF. GRUNDY GW. CREAGAN ET AND EVERSON RB.
(1975). Six families prone to ovarian cancer. Cancer. 36, 364-369.
GO RC. KING MC. BAILEY WJ. ELSTON RC. AND LYNCH HT.
(1983). Genetic epidemiology of breast cancer and associated
cancers in high risk families: I. segregation analysis. J. Natl
Cancer Inst.. 71, 455-461.
GREGGI S. GENUARDI M. BENEDETTI-PANICI P. CENTO R.
SCAMBIA G. NERI G AND MANCUSO S. (1990). Analysis of 138
consecutive ovarian cancer patients: incidence and characteristics
of familial cases. Gvnecol. Oncol.. 39, 300-304.
GROVER S. QUINN MA AND WEIDEMAN P. (1993). Patterns of
inheritance ofovarian cancer. An analysis from an ovarian cancer
screening program. Cancer. 72, 526- 530.
HARTGE P. SCHIFFMAN- MWH HOOVER R. MCGOWAN- L. LESHER L
AND NORRIS HJ. (1989). A case-control study of epithelial
ovarian cancer. Am. J. Obstet. Gvnecol.. 161, 10-16.
HARTGE P. WHITTEMORE AS. ITNYRE J. MCGOWAN L. CRAMER D
AND THE COLLABORATIVE OVARIAN CANCER GROUP. (1994).
Rates and risks ofovarian cancer in subgroups ofwhite women in
the United States. Obstet. Gvnecol.. 84, 760-764.
HOULSTON RS. COLLINS A. SLACK J. CAMPBELL S. COLLINS AP.
WHITEHEAD MI AND MORTON NE. (1991). Genetic epidemiol-
ogy ofovarian cancer: segregation analysis. Ann. Hum. Genet.. 55,
291 -299.
HOULSTON RS. BOURNE TH. COLLINS WP. WHITEHEAD MI.
CAMPBELL S AND SLACK J. (1993). Risk of ovarian cancer and
genetic relationship to other cancers in families. Hum. Hered.. 43,
111- 115.
KERBER RA AND SLATTERY ML. (1995). The impact of family
history on ovarian cancer risk. The Utah population database.
.4rch. Intern. Med.. 155, 905-912.
LEWIS ACW AND CLARE DAVISON BC. (1969). Familial ovarian
cancer. Lancet. 2, 235-237.
LI FP. RAPOPORT AH. FRAtUMENI JF AN-D JENSEN RD. (1970).
Familial ovarian carcinoma. J. .4m. Med. .4ss.. 214, 1559- 1561.
LIBER AF. (1950). Ovarian cancer in mother and five daughters.
Arch. Pathol.. 49, 280-290.Cancer ti relaives of ovarian cancer patients
%% A Auranen et al
284
LYNCH HT. GUIRGIS HA. ALBERT S. BRENNAN M. LYNCH J.
KRAFT C. POCEKAY D. VAUGHNS C AND KAPLAN A. (1974).
Familial association of carcinoma of the breast and ovary. Surg.
Gi-necol. Obst.. 138, 717- 724.
LYNCH HT. BEW'TRA C AND LYNCH JF. (1986). Familial ovarian
carcinoma. Clinical nuances. Am. J. Mfed., 81, 1073- 1076.
LYNCH HT. CONWAY T AND LYNCH J. (1991). Hereditary ovarian
cancer. Pedigree studies. part II. Cancer Genet. Cytogenet.. 52,
161- 183.
LYNCH HT. WATSON P. LYNCH JF. CONWAY TA AND FILI M.
(1993). Hereditary ovarian cancer. Heterogeneity in age at onset.
Cancer. 71, 573-581.
MECKLIN J-P AND JARVINEN HJ. (1991). Tumor spectrum in
Cancer Family Syndrome (hereditary nonpolyposis colorectal
cancer). Cancer. 68, 1109- 1112.
MIKI Y. SWENSEN J. SHATTUCK-EIDENS D. FUTREAL PA. HARSH-
MAN K. TAVTIGIAN S. LIU Q. COCHRAN C. BENNETT LM. DING
W. BELL R. ROSENTHAL J. HUSSEY C. TRAN T. MCCLURE M.
FRYE C. HATTIER T. PHELPS R. HAUGEN-STRANO A. KATCHER
H. YAKUMO K. GHOLAMI Z. SHAFFER D. STONE S. BAYER S.
WRAY C. BOGDEN R. DAYANANTH P. WARD J. TONIN P.
NAROD S. BRISTOW PK. NORRIS FH. HELVERING L. MORRI-
SON P. ROSTECK P. LAI M. BARRETT JC. LEWIS C. NEUHAUSEN
S. CANNON-ALBRIGHT L. GOLDGAR D. WISEMAN R. KAMB A
AND SKOLNICK MH. (1994). A strong candidate for the breast
and ovarian cancer susceptibility gene BRCAI. Science. 266, 66-
71.
NAROD SA. MADLENSKY L. BRADLEY L. COLE D. TONIN P. ROSEN
B AND RISCH HA. (1994). Hereditary and familial ovarian cancer
in southern Ontario. Cancer. 74, 2341 -2346.
NAROD SA. FORD D. DEVILEE P. BARKARDOTTIR RB. LYNCH HT.
SMITH SA. PONDER BAJ. WEBER BL, GARBER JE. BIRCH JM.
CORNELIS RS. KELSELL DP, SPURR NK. SMYTH E. HAITES N.
SOBOL H. BIGNON Y-J. CHANG-CLAUDE J. HAMANN U.
LINDBLOM A. BORG A. PIVER MS. GALLION HH. STRUEWING
JP. WHITTEMORE A, TONIN P. GOLDGAR DE. EASTON DF AND
THE BREAST CANCER LINKAGE CONSORTIUM. (1995). An
evaluation ofgenetic heterogeneity on 145 breast -ovarian cancer
families. Am. J. Hum. Genet.. 56, 254-264.
PARAZZINI F. NEGRI E. LA VECCHIA C. RESTELLI C AND
FRANCESCHI S. (1992). Family history of reproductive cancers
and ovarian cancer -isk: an Italian case-control study. Am. J.
Epidemiol.. 135, 35-40.
PIVER MS. BAKER TR. JISHI MF. SANDECKI AM. TSUKADA Y.
NATARAJAN N. METFTLIN CJ AND BLAKE CA. (1993). Familial
ovarian cancer. A report of 658 families from the Gilda Radner
familial ovarian cancer registry 1981 -1991. Cancer. 71, 582- 588.
SCHILDKRAU'T JM, RISCH -N AND THOMPSON D. (1989).
Evaluating genetic association among ovarian. breast and
endometrial cancer: evidence for a breast ovarian cancer relation-
ship. Am. J. Hum. Genet.. 45, 521-529.
SHAT`TUCK-EIDENS D. MCCLURE M. SIMARD J. LABRIE F. NAROD
S. COUCH F. HOSKINS K. WEBER B. CASTILLA L. ERDOS M.
BRODY L, FRIEDMAN L. OSTERMEYER E. SZABO C. KING M-C.
JHANWAR S. OFFIT K. NORTON L. GILEWSKI T. LUBIN M.
OSBORNE M. BLACK D. BOYD M. STEEL M. INGLES S. HAILE R.
LINDBLOM A, OLSSON H. BORG A. BISHOP DT. SOLOMON E.
RADICE P. SPATTISTA G. GAYTHER S. PONDER B. WARREN W.
STRATTON M. LIU Q. FUJIMARA F. LEWIS C. SKOLNICK MH
AND GOLDGAR DE. (1995). A collaborative survey of 80
mutations in the BRCA1 breast and ovarian cancer susceptibility
gene. J. Am. Med. Ass.. 273, 535-541.
SLATTERY ML AND KERBER RA. (1994). Family history of cancer
and colon cancer risk: the Utah population database. J. Natl
Cancer Inst., 86, 1618- 1626.
STEICHEN-GERSDORF E. GALLION HH. FORD D. GIRODET C.
EASTON DF. DICIOCCIO RA. EVANS G. PONDER MA. PYE C.
MAZOYER S. NOGUCHI T. KARENGUEVEN F. SOBOL H.
HARDOUIN A, BIGNON Y-J. PIVER MS. SMITH SA AND PONDER
BAJ. (1994). Familial site-specific ovarian cancer is linked to
BRCAJ on 17q12-21. Am. J. Hum. Genet., 55, 870-875.
TEPPO L. PUKKALA E AND LEHTONEN M. (1994). Data quality and
quality control ofa population-based cancer registry. Experience
in Finland. Acta Oncol.. 33, 365-369.
THOR L. PERSSON BH AND KJESSLER B. (1976). Familial ovarian
carcinoma. Uppsala J. Mfed. Sci.. 81, 189- 191.